Analysts at Jefferies have downgraded consumer health giant Kenvue to Hold, slashing their price target to $18. The move follows overwhelming shareholder approval for its acquisition by Kimberly-Clark and reflects concerns over limited upside and ongoing litigation risks.
As the NYSE and Nasdaq see a surge in 52-week extremes, we analyze four standout companies—two hitting new highs and two touching new lows—that offer compelling opportunities for patient investors looking toward 2026 and beyond.
The Washington Post has initiated a major restructuring, eliminating approximately one-third of its positions across all departments, including the closure of its sports desk and a reduction in international bureaus, as the newspaper grapples with financial pressures and shifting readership.
A recently enacted Florida statute requiring additional documentation for driver's license renewals has ignited a firestorm of criticism on social media, with many residents calling the process unnecessarily burdensome.
Amid a rapidly intensifying winter storm, a Gastonia Police K-9's tracking efforts proved critical in the safe recovery of a vulnerable 13-year-old boy who wandered from home.
Despite cooling national growth and pockets of weakness spreading across the Sunbelt, home prices increased in three-quarters of U.S. metro areas last quarter, as falling mortgage rates offered some relief to buyers.
UBS lowered its price target on Comcast (CMCSA) to $32, citing the company's ongoing transition in its broadband go-to-market approach. While some analysts see near-term pressure, others highlight the media giant's resilient cash flow and diversified segments.
Pfizer has announced positive Phase 2b results for its injectable obesity treatment, reporting significant weight reduction and a favorable safety profile as it gears up for a broad late-stage clinical program.
Amidst market volatility, DPM Metals (TSE:DPM) stands out with robust earnings growth and significant insider buying, signaling strong internal conviction in the company's future.
Simon Property Group unveils a major redesign plan for Tampa's International Plaza, part of a nationwide $250 million investment to transform traditional malls into modern lifestyle destinations with expanded outdoor spaces and curated experiences.
While most states have eliminated taxes on Social Security income, a handful continue to impose them, creating a significant financial consideration for retirees. Understanding both state and federal tax rules is crucial for retirement planning.
Major automakers have expressed support for the Trump administration's proposal to significantly relax future fuel efficiency targets, while urging adjustments to specific provisions on credit trading and vehicle classifications.
Publicly traded Bitcoin mining companies are facing a severe sell-off as Bitcoin's price decline erodes profitability and forces a strategic reckoning for the sector.
Food manufacturing giant Marzetti expands its portfolio with the acquisition of the fast-growing, family-inspired Japanese barbecue sauce brand Bachan's, signaling a major push into the premium condiment space.
In a congressional hearing, Treasury Secretary Scott Bessent retracted his earlier warning that tariffs are inflationary, citing current economic growth and moderating price pressures despite a year of trade measures.
For income-focused investors weighing the two U.S. oil titans, Chevron's higher dividend yield may tip the scales, despite ExxonMobil's larger scale and longer track record of payout growth.
In a move timed for the big game, PepsiCo is rolling back prices by up to 15% on its popular snack portfolio, including Lay's and Doritos, citing consumer pressure and a commitment to affordability.
The New York Times reports a surge in digital subscriptions and advertising revenue for 2025, contrasting sharply with The Washington Post's announcement of sweeping layoffs and section closures as the industry's divide widens.
Shares of Eli Lilly surged nearly 10% after the pharmaceutical giant smashed fourth-quarter estimates and issued a bullish 2026 outlook, powered by unprecedented demand for its GLP-1 drugs Mounjaro and Zepbound.
GSK delivered a robust fourth-quarter performance, surpassing its medium-term targets ahead of schedule. However, the company's deliberately conservative guidance for 2026 has left the market debating whether this signals prudent management or a missed opportunity to inspire greater confidence.
